How to Buy Neurocrine Biosciences Stock
Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions.
Neurocrine Biosciences stock last closed at $161.62, up 2.1% from the previous day, and has increased 28.47% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.64 percentage points. Neurocrine Biosciences stock is currently +32.33% from its 52-week low of $122.14, and -4.69% from its 52-week high of $169.57.
There are currently 100.55M NBIX shares outstanding. The market cap of NBIX is $16.25B. In the last 24 hours, 906,000 NBIX shares were traded.
How to Buy Neurocrine Biosciences Stock
Wondering how to invest in Neurocrine Biosciences stock? Here's how.
- Choose where to buy Neurocrine Biosciences stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Neurocrine Biosciences stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Choose your method of payment and add your details.
- Analyze Neurocrine Biosciences stock: The Neurocrine Biosciences ticker symbol is NBIX. Is Neurocrine Biosciences stock a good investment? Should you buy shares of NBIX? How do NBIX's underlying business fundamentals look? Do top analysts think Neurocrine Biosciences is a good buy? Why has NBIX's stock price moved recently? (Hint: Our stock research website can help you evaluate if NBIX is a good stock to buy).
- Execute your NBIX purchase: Decide if you will purchase NBIX shares at the current market price or use a limit order to purchase NBIX shares at a particular price.
- Get notifications regarding your NBIX position: Create a watchlist to track your investment in Neurocrine Biosciences shares.
Step 1: Choose where to buy Neurocrine Biosciences stock
You need an online brokerage account to access the NASDAQ market and buy NBIX shares.
Our preferred brokerage: eToro
Based on our research, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global markets: From Technology to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal info so you are able to buy NBIX today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create your new brokerage account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've finished signing up on a good stock buying app, you need to deposit funds:
Watch the tutorial below to see the process of transferring money into your new investment account.
Step 4: Analyze Neurocrine Biosciences stock
Once you have identified the best place to buy Neurocrine Biosciences stock, it's very important to evaluate their stock before you invest, so you actually understand the risk as well as the upside.
Neurocrine Biosciences stock at a glance
NBIX Due Diligence Checks
WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on NBIX's stock page.
How is NBIX stock valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge NBIX's intrinsic value.
Using relative valuations measures:
- NBIX could be undervalued based on its P/E ratio of 24.09x, relative to Drug Manufacturers - Specialty & Generic industry P/E ratio of -5.07x
- NBIX may be overvalued based on its P/B ratio of 4.77x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 1.5x
- NBIX may be overvalued based on its PEG ratio of 1.08x
You can access more valuation analysis on NBIX's stock here.
Is NBIX a healthy company?
Signs that NBIX is financially healthy:
- NBIX profit margin has gone up from 12.7% to 21.6% in the past year.
- Total NBIX debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the NBIX balance sheet.
- There are more short-term assets than short-term liabilities on the NBIX balance sheet.
- NBIX earnings of $937.50M is not enough to cover its interest payments.
- NBIX's operating cash flow of $863.70M allows it to safely service it's debt of $406.20M.
Signs that NBIX is not financially healthy:
- NBIX has a relatively high debt to equity ratio of 0.44.
Is NBIX stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 18 Equities analysts who research NBIX, the consensus analyst rating on Neurocrine Biosciences is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Most Recent NBIX Analyst Forecasts
Yigal Nochomovitz, a top 6% analyst from Citigroup maintains NBIX with a strong buy rating and raises their NBIX price target from $242.00 to $246.00, on May 6, 2026.
Jeffrey Hung, a top 7% analyst from Morgan Stanley maintains NBIX with a hold rating and raises their NBIX price target from $185.00 to $191.00, on May 6, 2026.
David Amsellem, a top 5% analyst from Piper Sandler maintains NBIX with a strong buy rating and raises their NBIX price target from $190.00 to $207.00, on May 6, 2026.
Piper Sandler's David Amsellem raised their price target on Neurocrine Biosciences (NASDAQ: NBIX) by 8.9% from $190 to $207 on 2026/05/06. The analyst maintained their Strong Buy rating on the stock.
Neurocrine Biosciences reported its Q1 2026 earnings.
Raising their price target, Amsellem big-pictured that the stock's risk/reward profile is "highly attractive," particularly when factoring in the contribution from Vykat XR with the pending acquisition of Soleno Therapeutics.
More significantly, the analyst opined, Neurocrine Biosciences stock is trading at a multiple of 9x Piper Sandler's 2027 pro forma EBITDA estimate, "in the context of a company that will soon have three assets with lengthy exclusivity runways, two of which are quite early in their commercial lives."
Earnings Report
For Q1 2026, Neurocrine Biosciences reported:
- EPS of $1.94, which beat the Zacks Consensus Estimate of $1.68 and Q1 2025's $0.08.
- Revenue of $814.5M, which beat the Zacks Consensus Estimate by 9.8% and Q1 2025's $572.6M.
For FY 2026, management guided:
- INGREZZA Net Product Sales of $2.7B to $2.8B.
CEO Kyle W. Gano, Ph.D., commented: "Neurocrine's strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and diversify across therapeutic areas.
"We delivered $811 million in net product sales, representing 44% year-over-year growth, driven by continued strong demand for INGREZZA and CRENESSITY® (crinecerfont).
"Our recently announced agreement to acquire Soleno Therapeutics further underscores our commitment to address conditions with significant unmet need and accelerate revenue growth.
"With multiple first-in-class commercial medicines and the deepest pipeline in our history, Neurocrine is well-positioned to deliver transformative therapies for patients and drive sustained growth."
Yatin Suneja, a top 3% analyst from Guggenheim reiterates NBIX with a strong buy rating and maintains their NBIX price target from $175.00 to $175.00, on May 6, 2026.
Laura Chico, a top 4% analyst from Wedbush maintains NBIX with a buy rating and raises their NBIX price target from $166.00 to $176.00, on May 6, 2026.
You can dive deeper into what analysts are forecasting on the Neurocrine Biosciences stock forecast page.
NBIX Technicals
NBIX Performance Metrics
Last year, NBIX earnings were $668.60M. Over the past 5 year, NBIX's earnings have gone up by 9.21% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 5.29%.
Last year, NBIX revenue was $3.10B. Over the last five year, NBIX's revenue has grown by 24.3% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 9.32%.
Dig into NBIX's earnings and revenue performance here.
Are NBIX executives and large shareholders buying or selling the stock?
In the past year, insiders at NBIX have sold more shares than they have bought.
Stephen A. Sherwin, Director of NBIX, was the latest NBIX insider to buy. They bought $804,600.00 worth of NBIX shares on Jun 5, 2026.
Dig into more about who owns NBIX stock here.
Does NBIX provide a stable income stream?
No, Neurocrine Biosciences doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your NBIX purchase
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally fine for most investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a specific price limit, use a limit order.
Press the Open button and your broker will place the order.
If you require additional help with buying stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your NBIX position
Now that you own some shares in NBIX, you'll want to keep up with your company.
Add NBIX to a watchlist to track the latest developments regarding your NBIX stock.
NBIX Feed
How to Buy Stock in Neurocrine Biosciences
To summarize, here are the 6 steps to buy Neurocrine Biosciences stock:
- Choose where to buy Neurocrine Biosciences stock
- Sign up for your brokerage account
- Put funds into your brokerage account
- Analyze Neurocrine Biosciences stock
- Execute your NBIX purchase
- Get notifications regarding your NBIX position
If you need a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest news on your new investment in Neurocrine Biosciences, get started below.
Related Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.